Slow intravenous iron administration does not aggravate oxidative stress and inflammatory biomarkers during hemodialysis: A comparative study between iron sucrose and iron dextran

American Journal of Nephrology

Volumn 27, Issue 6, 2007, Pages 572-579

  Malindretos, Pavlos ^a   Sarafidis, Pantelis A ^a   Rudenco, Igor ^a   Raptis, Vasilios ^a   Makedou, Kali ^a   Makedou, Areti ^a   Grekas, Dimirios M ^a  

^a AHEPA UNIVERSITY HOSPITAL   (Greece)

Author keywords

Hemodialysis; Inflammation; Intravenous iron administration; Oxidative stress

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COSMOFER; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; INTERLEUKIN 6; IRON DEXTRAN; OXIDIZED LOW DENSITY LIPOPROTEIN; TRANSFERRIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHRONOPHARMACOLOGY; CLINICAL ARTICLE; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; INFLAMMATION; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; FERRIC COMPOUNDS; HEMATINICS; HUMANS; INFLAMMATION MEDIATORS; INFUSIONS, INTRAVENOUS; INTERLEUKIN-6; IRON-DEXTRAN COMPLEX; KIDNEY FAILURE, CHRONIC; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATIVE STRESS; RENAL DIALYSIS; SERUM ALBUMIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 35548938637     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107928     Document Type: Article

References (39)

1. Hsu Chi-Yan, Mcculloch C, Curhhan G: Epidemiology of anemia associated with chronic renal insufficiency among adults in the United States: results from the third national health and nutrition examination survey. J Am Soc Nephrol 2002;13:504-510.
2. Collins A, Ma J, Ebben J: Patient survival is associated with hematocrit (HCT) level. J Am Soc Nephrol 1997;8:190A.
3. Valderrabano F, Jofre R, Lopez-Gomez JM: Quality of life in end-stage renal disease patients. Am J Kidney Dis 2001;38:443-464.
4. NKF-K/DOQI clinical practice guidelines for anemia of chronic kidney disease; update 2000. Am J Kidney Dis 2001;37(suppl 1):182-238.
5. Eschbach JW, Ergie JC, Downing MR, et al: Correction of the anemia of end stage renal disease with recombinant human erythropoietin: results of a combined phase I and II clinical trial. N Engl J Med 1987;316:73-78.
6. Danielson B: R-HuEPO hyporesponsiveness - who and why? Nephrol Dial Transplant 1995;10(suppl 2):69-73.
7. Macdougall IC, Tucker B, Thompson J, et al: A randomized controlled study of iron supplementation in patients treated with erythropoietin. Kidney Int 1996;50:1694-1699.
8. Zanen A, Adriaansen H, Van Bommel E, et al: 'Oversaturation' of transferrin after intravenous ferric gluconate (Ferrlecit®) in haemodialysis patients. Nephrol Dial Transplant 1996;11:820-824.
9. Kooistra M, Kersting S, Gosriwatana I: Non-transferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest 2002;32(suppl 1):36-41.
10. Parkkinen J, Von Bonsdorff L, Peltonen S, et al: Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. Nephrol Dial Transplant 2000;15:1827-1834.
11. Deicher R, Ziali F, Cohen G, et al: High dose parenteral iron sucrose depresses neutrophil intracellular killing capacity. Kidney Int 2003;64:728-736.
12. Weiss G, Meusburger E, Radacher G, et al: Effect of iron treatment on circulating cytokine levels in ESRD patients receiving recombinant human erythropoietin. Kidney Int 2003;64:572-578.
13. Gutterridge J, Rowley D, Halliwell B: Superoxide-dependent formation of hydroxyl radicals in the presence of iron salts. Biochem J 1981;199:263-265.
14. Gutterridge J, Rowley D, Halliwell B: Superoxide-dependent formation of hydroxyl radicals and lipid peroxidation in the presence of iron salts. Biochem J 1982;206:605-609.
15. Berliner J, Heinecke J: The role of oxidized lipoproteins in atherogenesis. Free Rad Biol Med 1996;20:707-727.
16. Rooyakkers T, Stroes E, Kooistra M, et al: Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo. Eur J Clin Invest 2002;32(suppl 1):9-16.
17. Zager R, Johnson A, Hanson S, Wasse H: Parenteral iron formulations: A comparative toxicologic analysis and mechanisms of cell injury. Am J Kidney Dis 2002;40:90-103.
18. Tribble D, Aw T, Jones D: The pathophysiological significance of lipid peroxidation in oxidative cell injury. Hepatology 1987;7:377-386.
19. Bolton C, Downs L, Victory J, et al: Endothelial dysfunction in chronic renal failure: roles of lipoprotein oxidation and pro-inflammatory cytokines. Nephrol Dial Transplant 2001;16:1189-1197.
20. Drüeke T, Witko-Sarsat V, Massy Z, et al: Iron therapy, advanced products, and carotid intima-media thickness in end-stage renal disease. Circulation 2002;106:2212-2217.
21. Malindretos P, Sioulis A, Avgeriou E, et al: Association between intensive intravenous iron treatment and angina pectoris in hemodialysis patients. Clin Nephrol 2006;66:312-313.
22. Bayes B, Pastor MC, Bonal J, et al: Oxidative stress, inflammation and cardiovascular mortality in haemodialysis. Role of seniority and intravenous ferrotherapy: analysis at 4 years of follow-up. Nephrol Dial Transplant 2005;10:1093-1099.
23. Endemann D, Schiffrin E: Endothelial dysfunction. J Am Soc Nephrol 2004;15:1983-1992.
24. Sinha M, Gaze D, Tippins J, et al: Ischemia modified albumin is a sensitive marker of myocardial ischemia after percutaneous coronary intervention. Circulation 2003;107:2403-2405.
25. Sharma R, Gaze D, Pellerin D, et al: Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis 2006;47:493-502.
26. Stuveling E, Stephan J, Bakker L, et al: Biochemical risk markers: a novel area for better prediction of renal risk? Nephrol Dial Transplant 2005;20:497-508.
27. Peuchant E, Carbonneau M, Dubourg L, et al: Lipoperoxidation in plasma and red blood cells of patients undergoing haemodialysis: vitamins A, E, and iron status. Free Rad Biol and Med 1994;16:339-346.
28. Cristol J, Bosc J, Badiou S, et al: Erythropoietin and oxidative stress in haemodialysis: beneficial effects of vitamin E supplementation. Nephrol Dial Transplant 1997;12:2312-2317.
29. Salahudeen A, Oliver B, Bower J, Roberts J: Increase in plasma esterified F 2 isoprostanes following intravenous iron infusion in patients on hemodialysis. Kidney Int 2001;60:1525-1531.
30. Tovbin D, Mazor T, Vorobiov M, et al: Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. Am J Kidney Dis 2002;40:1005-1012.
31. Agarwal R, Vasavada N, Sachs N, et al: Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004;65:2279-2289.
32. Roob J, Khoschsorur G, Tiran A, et al: Vitamin E oxidative stress induced by intravenous iron in patients on hemodialysis. J Am Soc Nephrol 2000;11:539-549.
33. Guz G, Glorieux G, De Smet R, et al: impact of iron sucrose therapy on leukocyte surface molecules and reactive oxygen species in haemodialysis patients. Nephrol Dial Transplant 2006;21:2834-2840.
34. Pai AB, Boyd AV, McQuade CR, et al: Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis. Pharmacotherapy 2007;27:343-350.
35. Borawski J, Gozdzikiewicz J, Abramowicz P, et al: Endothelial injury markers with high-dose intravenous iron therapy in renal failure. Clin Appl Thromb Hemost 2004;10:403-406.
36. Kirmizis D, Tsiandoulas A, Pangalou M, et al: Validity of plasma fibrinogen, D-dimer, and the von Willebrand factor as markers of cardiovascular morbidity in patients on chronic hemodialysis. Med Sci Monit 2006;12:55-62.
37. Owen W, Lowrie E: C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 1998;54:627-636.
38. Kato A, Odamaki M, Takita T, et al: C-reactive protein is a predictor of short-term mortality in hemodialysis patients. Am J Nephrol 2001;21:176-178.
39. Goldstein SL, Currier H, Watters L, et al: Acute and chronic inflammation in pediatric patients receiving hemodialysis. J Pediatr 2003;143:653-657.